The Interleukin 13 α2 receptor (IL-13Rα2) is a glioma-restricted cell surface cytokine receptor and molecular target for novel glioma therapeutics. Jensen and colleagues report on the genetic engineering of the IL13 zetakine, a chimeric T-cell antigen receptor that uses an IL13Rα2 selective IL13 mutein extracellular targeting domain. IL13 zetakine-expressing, cytotoxic T-lymphocytes display redirected IL13Rα2-specific antitumor effector function and are capable of eradicating established orthotopic GBM xenografts. Initial adoptive therapy trials are underway to evaluate the clinical feasibility and safety of this approach in patients with recurrent GBM. For details, see the article by Kahlon et al. on page 9160 of this issue.

[Table of Contents]